Clinical trials
for patients

The primary objective of Part B is to further evaluate the safety of the study drug and how well it is tolerated by the body in a larger number of people with myasthenia gravis (MG). The study will also assess whether the study drug is effective in people with generalized myasthenia gravis (gMG) and ocular myasthenia gravis (oMG).

The purpose of this trial is to test an investigational drug called daraxonrasib (RMC-6236). Daraxonrasib is an investigational drug, which means that it has not been approved by the Spanish Agency for Medicines and Health Products (AEMPS) or by any other health authority in any country. Daraxonrasib is currently being investigated in other ongoing studies in pancreatic cancer, and its safety, tolerability, and efficacy are being evaluated in comparison with usual clinical practice.

The purpose of this trial is to continue evaluating whether the investigational drug afimkibart, when administered over a longer period, is safe and effective for moderate-to-severe atopic dermatitis, and to determine the long-term effects, both positive and negative, of afimkibart on atopic dermatitis. You are being asked to participate in this trial because you have moderate-to-severe atopic dermatitis, participated in study CS45570, and responded to treatment with afimkibart.

The purpose of this clinical study is to determine whether obrixtamig in combination with atezolizumab, carboplatin, and etoposide (standard chemotherapy) is more effective than standard chemotherapy alone in treating people with advanced small cell lung cancer.

The main objectives of the study are as follows: Part A (Phase 1, safety run-in, dose escalation): To determine whether BNT314 in combination with pumitamig can be administered safely without causing serious side effects in participants. Part B (Phase 1, dose optimization): To assess whether BNT314 in combination with pumitamig and standard chemotherapy is safe for participants and to determine the appropriate dose of BNT314 to be used in Part C. Part C (Phase 2, randomization versus standard tr...

The purpose of this study is to help researchers understand whether JNJ-95804306 is safe and effective for treating people with acute myeloid leukemia (AML), myelodysplastic neoplasms (MDS, also known as myelodysplastic syndrome), chronic lymphocytic leukemia (CLL), or small lymphocytic lymphoma (SLL). The study aims to determine a dose—the amount of medication taken at one time—of JNJ-95804306 that can safely and effectively treat AML, MDS, CLL, and SLL. It will also assess the sid...

The main objective of this study is to evaluate the safety and tolerability of EGL-001 in participants with selected advanced and/or metastatic solid tumors whose disease has progressed after previously deriving benefit from standard-of-care treatment with an immune checkpoint inhibitor.

The purpose of this study is to compare the effects, both beneficial and adverse, of cevostamab in combination with pomalidomide and dexamethasone with the standard treatment selected by the study physician—daratumumab in combination with pomalidomide and dexamethasone (DPd), elotuzumab in combination with pomalidomide and dexamethasone (EPd), or carfilzomib in combination with dexamethasone (Kd)—in people with multiple myeloma.

The primary objective of the trial is to determine: the best way to safely administer T3P to patients; the side effects of T3P and how they can be managed; and whether T3P can shrink or control cancers.

The primary objective of this trial is to determine whether RO7589831 administered at different doses has effects, whether positive or negative, as well as what happens to RO7589831 once it enters the body and how it acts in the body and on your disease.

The objective of this study is to determine what dose of the study drug, called “CABA-201,” can be safely administered to patients with idiopathic inflammatory myopathy (IIM) and juvenile idiopathic inflammatory myopathy (JIIM) or myositis. Although the cause is not well understood, JIIM and some subtypes of IIM, including dermatomyositis (DM), antisynthetase syndrome (ASyS), and immune-mediated necrotizing myopathy (IMNM), are believed to involve B cells, which cause the body to attack differen...

This study is being conducted to determine whether the study drug, momelotinib, works to improve anemia, a condition associated with myelodysplastic syndrome (MDS); whether it makes you feel better; whether it is safe and well tolerated; and which dose of the drug works best. This study will be conducted in adult participants aged 18 years and older with anemia associated with MDS.

The objective of this study is to compare the effects of JNJ-79635322 with those of teclistamab. Teclistamab is already used to treat adults with multiple myeloma.

The objective is to study the samples to understand their responses to the study drug and to obtain more information about small cell lung cancer.

The objective of this research is to evaluate whether the study drug NI-1801, as a single agent, in combination with pembrolizumab, in combination with paclitaxel (randomized cohort I), or in combination with pembrolizumab and standard chemotherapy-based treatment with paclitaxel (randomized cohort II), has potential beneficial effects and is safe for patients with these types of cancer.

The primary objective is to evaluate the safety and tolerability of GSK5533524 as monotherapy in PROC and to select the dose(s) for evaluation in Part 1b.

The objective of this study is to evaluate potential new cancer treatments for people with tumors similar to yours. The sponsor wants to find out what effects, positive or negative, these treatments have on you and your disease.

The objective of this trial is to provide continued treatment with remibrutinib and collect long-term safety data in patients who have completed a Novartis remibrutinib trial, who have benefited from treatment, and who cannot obtain remibrutinib locally.

The objective of this study is to determine whether an investigational drug called MB-CART2019.1 is more effective than a second standard chemotherapy treatment for your disease. This study will also investigate the safety of MB-CART2019.1 when administered to patients and will determine whether there are any changes in their quality of life.

The objective of this study is to provide continued access to elranatamab (as monotherapy) and to monitor the safety of this drug in participants with multiple myeloma who continue to show clinical benefits in the Pfizer-sponsored main study, which is scheduled to conclude.